Abstract
It has been demonstrated that cholestane-3β, 5α, 6β-triol (CT) and its derivatives show remarkably preventing effects on the development of the experimental hypercholesterolemia and atherosclerosis in cholesterol-fed-rabbits, rats and chickens, and that the compounds lower the elevated lipemia caused by oral administration of the vegetable oil in rats (1). Their effects on the metabolic fate of cholesterol have been investigated (2). The present experiments are the preclinical studies of the compounds including acute, subacute and chronic toxicities in mice, rats, dogs and monkeys.
